EP1372392A4 - Nicotine-containing oral dosage form - Google Patents
Nicotine-containing oral dosage formInfo
- Publication number
- EP1372392A4 EP1372392A4 EP02721544A EP02721544A EP1372392A4 EP 1372392 A4 EP1372392 A4 EP 1372392A4 EP 02721544 A EP02721544 A EP 02721544A EP 02721544 A EP02721544 A EP 02721544A EP 1372392 A4 EP1372392 A4 EP 1372392A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nicotine
- dosage form
- oral dosage
- containing oral
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27860601P | 2001-03-26 | 2001-03-26 | |
US278606P | 2001-03-26 | ||
PCT/US2002/008914 WO2002076211A1 (en) | 2001-03-26 | 2002-03-22 | Nicotine-containing oral dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1372392A1 EP1372392A1 (en) | 2004-01-02 |
EP1372392A4 true EP1372392A4 (en) | 2004-06-23 |
Family
ID=23065632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02721544A Withdrawn EP1372392A4 (en) | 2001-03-26 | 2002-03-22 | Nicotine-containing oral dosage form |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1372392A4 (en) |
JP (1) | JP2004525928A (en) |
CN (2) | CN101301275A (en) |
AR (1) | AR033444A1 (en) |
AU (1) | AU2002252470B2 (en) |
BR (1) | BR0208382A (en) |
CA (1) | CA2440713A1 (en) |
MX (1) | MXPA03008762A (en) |
NZ (1) | NZ528167A (en) |
PL (1) | PL364621A1 (en) |
WO (1) | WO2002076211A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
ES2654062T3 (en) * | 2003-07-24 | 2018-02-12 | Glaxosmithkline Llc | Oral Dissolution Films |
GB0320854D0 (en) | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
EP1691631A4 (en) | 2003-11-07 | 2012-09-05 | Us Smokeless Tobacco Co | Tobacco compositions |
PL1786272T3 (en) * | 2004-08-11 | 2015-02-27 | Intercontinental Great Brands Llc | Warming compositions and delivery systems therefor |
US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20080131508A1 (en) * | 2006-12-01 | 2008-06-05 | Cephalon, Inc | Oral transmucosal nicotine dosage form |
GB2468424B (en) * | 2007-04-02 | 2011-11-09 | Parkinson S Inst | Methods and compositions for reduction of side effects of therapeutic treatments |
KR101122469B1 (en) | 2007-04-02 | 2012-07-12 | 파킨슨즈 인스티튜트 | Methods and compositions for reduction of side effects of therapeutic treatments |
DE102008012015A1 (en) * | 2008-03-01 | 2009-09-10 | Südzucker AG Mannheim/Ochsenfurt | Improved isomalt-containing compresses and processes for their preparation |
EP2536409A4 (en) * | 2010-02-18 | 2013-07-17 | Jatin Vasant Thakkar | Nicotine-containing soft gelatin pastilles |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
UA112974C2 (en) * | 2010-09-16 | 2016-11-25 | Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид | NICOTINE COMPOSITION (OPTIONS) |
CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
US9044035B2 (en) * | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
AR096223A1 (en) * | 2013-05-10 | 2015-12-16 | Glaxosmithkline Llc | NICOTINE PILL FOR ORAL ADMINISTRATION |
CN104132895B (en) * | 2014-07-08 | 2017-08-25 | 国家烟草质量监督检验中心 | The buffer system of total alkaloid tobacco and tobacco product is determined suitable for continuous flow method |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
AU2018205529B2 (en) | 2017-01-06 | 2023-08-10 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
SE541358C2 (en) * | 2017-05-30 | 2019-08-13 | Enorama Pharma Ab | Nicotine-containing chewing gum compositions |
CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
CN115003281A (en) * | 2020-01-15 | 2022-09-02 | 麦克内尔股份公司 | Pastille |
US20220313678A1 (en) * | 2021-04-06 | 2022-10-06 | Altria Client Services Llc | Spray dried nicotine for inclusion in oral products |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593684A (en) * | 1993-08-04 | 1997-01-14 | Pharmacia Ab | Method and therapeutic system for smoking cessation |
US5662920A (en) * | 1993-07-26 | 1997-09-02 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
DE19536394A1 (en) * | 1995-09-29 | 1997-04-03 | Basf Ag | Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt |
DE19639342C2 (en) * | 1996-09-25 | 1998-07-16 | Suedzucker Ag | Chewing gum containing a sweetener |
US6322806B1 (en) * | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
-
2002
- 2002-03-22 CN CNA2008101253651A patent/CN101301275A/en active Pending
- 2002-03-22 CA CA002440713A patent/CA2440713A1/en not_active Abandoned
- 2002-03-22 BR BR0208382-5A patent/BR0208382A/en not_active IP Right Cessation
- 2002-03-22 EP EP02721544A patent/EP1372392A4/en not_active Withdrawn
- 2002-03-22 CN CNA028073339A patent/CN1553771A/en active Pending
- 2002-03-22 WO PCT/US2002/008914 patent/WO2002076211A1/en active IP Right Grant
- 2002-03-22 JP JP2002574739A patent/JP2004525928A/en active Pending
- 2002-03-22 PL PL02364621A patent/PL364621A1/en not_active Application Discontinuation
- 2002-03-22 MX MXPA03008762A patent/MXPA03008762A/en active IP Right Grant
- 2002-03-22 AR ARP020101068A patent/AR033444A1/en unknown
- 2002-03-22 NZ NZ528167A patent/NZ528167A/en not_active IP Right Cessation
- 2002-03-22 AU AU2002252470A patent/AU2002252470B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662920A (en) * | 1993-07-26 | 1997-09-02 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
US5593684A (en) * | 1993-08-04 | 1997-01-14 | Pharmacia Ab | Method and therapeutic system for smoking cessation |
Non-Patent Citations (1)
Title |
---|
See also references of WO02076211A1 * |
Also Published As
Publication number | Publication date |
---|---|
AR033444A1 (en) | 2003-12-17 |
WO2002076211A1 (en) | 2002-10-03 |
CN101301275A (en) | 2008-11-12 |
JP2004525928A (en) | 2004-08-26 |
CN1553771A (en) | 2004-12-08 |
MXPA03008762A (en) | 2004-02-18 |
BR0208382A (en) | 2004-06-15 |
AU2002252470B2 (en) | 2008-05-22 |
PL364621A1 (en) | 2004-12-13 |
NZ528167A (en) | 2005-04-29 |
EP1372392A1 (en) | 2004-01-02 |
CA2440713A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1372392A4 (en) | Nicotine-containing oral dosage form | |
EG23943A (en) | Flash-melt oral dosage formulation | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
PL367180A1 (en) | Stabilized oral pharmaceutical composition | |
HUP0203204A3 (en) | Oral dosage forms | |
GB0117618D0 (en) | Pharmaceutical dosage form | |
EP1383518A4 (en) | Oral delivery of macromolecules | |
IL154012A0 (en) | Hydrogel-driven drug dosage form | |
PT1362582E (en) | Enrobed solid dosage form | |
HUP0301697A3 (en) | Oral solid dose vaccine | |
PL365518A1 (en) | Oral composition | |
HUP0400850A3 (en) | Oral pharmaceutical compositions | |
GB0117619D0 (en) | Pharmaceutical dosage form | |
IL166337A0 (en) | Oral administration of calctionin | |
HUP0500638A2 (en) | Flashmelt oral dosage formulation | |
GB2383989B (en) | Improved oral medicine dispenser | |
HUP0401599A3 (en) | Extended release oral dosage form | |
EP1429615A4 (en) | Oral vaccines | |
EP1357898A4 (en) | Improved controlled release oral dosage form | |
EP1361866A4 (en) | Emulsions as solid dosage forms for oral administration | |
GB0014497D0 (en) | Oral dosage form | |
PL373799A1 (en) | Flashmelt oral dosage formulation | |
HK1047232A1 (en) | Oral dosage forms | |
PL341178A1 (en) | Oral pharmaceutical dosage forms | |
GB9925069D0 (en) | Oral dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030922 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040507 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/465 B Ipc: 7A 61K 9/20 A |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1061622 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20071108 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GLAXOSMITHKLINE LLC |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1061622 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20101001 |